Christopher Vann
Senior VP & COOMr. Christopher Vann, also known as Chris, has been Senior Vice President and Chief Operating Officer at Autolus Therapeutics Plc. since October 2016. He serves as Director of Alliance for Regenerative Medicine. Mr. Vann has been Chief Operating Officer of Autolus Limited since July 2017. Prior to this, he worked at Hoffmann-La Roche’s Swiss headquarters from February 1994 to September 2016, most recently serving as its Commercial Director from December 2011 to September 2016 where he was primarily responsible for leading the lung cancer commercial team and general management of the Tarceva brand. He has significant experience of global lifecycle management of oncology products as well as implementing marketing strategy at a regional and national level which includes launching several oncology, immunology and transplant products in the United States, United Kingdom, Romania, Russia, South Africa and countries in Asia, including Japan. Mr. Vann holds a B.S. in Toxicology and Pharmacology from the School of Pharmacy, University of London.
Positions
- Company NameAutolus Therapeutics plcStock CodeAUTLPositionSenior VP & COOColleagues
- CMChristian Martin ItinCEO & Director
- MWMichael Weston BonneyIndependent Chairman of the Board
- MPMartin PuleFounder, Senior VP & Chief Scientific Officer
- RFRobert F. DolskiSenior VP & CFO
- PMPatrick McIlvennySenior VP of Finance, Chief Accounting Officer & Principal Accounting Officer
- LCLinda Cathavina BainIndependent Non-Executive Director
- CMCynthia Marie ButittaIndependent Non-Executive Director
- WDWilliam Douglas YoungIndependent Non-Executive Director
